Frequently Asked Questions
What is the CiPA initiative?
The Comprehensive in vitro Proarrhythmia Assay (CiPA) is an FDA/HESI initiative that provides a new paradigm for cardiac safety testing. It combines human iPSC-cardiomyocyte assays, ion channel data, and in silico modeling to predict pro-arrhythmic risk more accurately than traditional hERG-only screening. CiPA is now part of ICH S7B/E14 guidelines.
Why are iPSC-cardiomyocytes better than hERG assays?
hERG assays only measure one potassium channel, while real cardiac toxicity involves multiple ion channels and complex cellular physiology. iPSC-cardiomyocytes express all cardiac ion channels, contract, and show human-specific responses. They detect cardiotoxicity that hERG misses and clear safe drugs that hERG falsely flags as dangerous.
How do cardiac organoids differ from 2D cardiomyocytes?
Cardiac organoids self-organize into 3D structures with chamber-like organization and multiple cell types (cardiomyocytes, fibroblasts, endothelial cells). They model structural cardiotoxicity, developmental effects, and tissue-level responses that 2D monolayers cannot capture. Some organoids even recapitulate early heart development.
What is structural cardiotoxicity?
Structural cardiotoxicity refers to drug-induced damage to heart muscle cells themselves, as opposed to electrical effects. Cancer drugs like doxorubicin and tyrosine kinase inhibitors can cause cardiomyocyte death, fibrosis, and heart failure. Structural toxicity is detected by troponin release, sarcomere disorganization, and mitochondrial dysfunction in cardiac models.
Can cardiac models predict patient-specific responses?
Yes, iPSC-cardiomyocytes derived from specific patients capture their genetic background and drug response phenotypes. Patients with long QT syndrome, hypertrophic cardiomyopathy, or other genetic heart conditions can have their cells used to test drug safety for their specific condition before prescribing.
How is contractility measured in cardiac models?
Contractility is measured using video microscopy tracking of beating motion, impedance-based sensors that detect cell movement, or direct force measurements in engineered heart tissues. Parameters include beat rate, contraction amplitude, velocity of shortening, and relaxation time - all clinically relevant for assessing cardiac function effects.
What drugs have been withdrawn for cardiac toxicity?
Notable withdrawals include cisapride, terfenadine, and rofecoxib (Vioxx) - all of which showed cardiac toxicity in humans that animal models failed to predict. These failures drove development of human-based cardiac models. Modern iPSC-cardiomyocyte assays correctly identify these drugs as cardiotoxic, validating their predictive value.
How do heart-on-chip platforms add value?
Heart-on-chip platforms add mechanical stretching to simulate cardiac workload, perfusion for nutrient delivery and drug exposure, and integrated sensors for real-time monitoring. The mechanical stimulation improves cardiomyocyte maturation and function, making the models more physiologically relevant for drug testing.